Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of liposomal irinotecan + oxaliplatin + 5-fluorouracil/leucovorin versus nab-paclitaxel + gemcitabine in previously untreated metastatic pancreatic adenocarcinoma
2018-003585-14Phase 3Completed
- Sponsor
- Ipsen
- Start
- Jan 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nanoliposomal irinotecan, oxaliplatin, fluorouracil, folinic acid, paclitaxel and 1 more in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Ipsen. Primary endpoint: Overall survival. Started Jan 2020; status: completed.
02
Drugs
nanoliposomal irinotecanoxaliplatinfluorouracilfolinic acidpaclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2018-003585-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003585-14.